{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Positive+Breast+Carcinoma&page=11", "query": { "condition": "HER2 Positive Breast Carcinoma", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 846, "total_pages": 85, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Positive+Breast+Carcinoma&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Positive+Breast+Carcinoma&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T17:34:15.480Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07205822", "title": "A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-10-30", "completion_date": "2028-02-02", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-15T17:34:15.480Z", "location_count": 6, "location_summary": "Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more", "locations": [ { "city": "Largo", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07205822" }, { "nct_id": "NCT00524277", "title": "Vaccine Therapy in Treating Patients With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GP2 peptide + GM-CSF vaccine", "type": "BIOLOGICAL" }, { "name": "GM-CSF (sargramostim)", "type": "BIOLOGICAL" }, { "name": "AE37 + GM-CSF vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "San Antonio Military Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 456, "start_date": "2007-01", "completion_date": "2017-03-31", "has_results": false, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-10-15T17:34:15.480Z", "location_count": 11, "location_summary": "Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 7 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524277" }, { "nct_id": "NCT06018337", "title": "A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "DB-1303/BNT323", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 541, "start_date": "2024-01-18", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-15T17:34:15.480Z", "location_count": 44, "location_summary": "Tucson, Arizona • Fullerton, California • Los Angeles, California + 39 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06018337" }, { "nct_id": "NCT00021255", "title": "Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Herceptin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 3222, "start_date": "2001-04", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-11-15", "last_synced_at": "2026-10-15T17:34:15.480Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021255" }, { "nct_id": "NCT02326974", "title": "T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER-2 Positive Breast Cancer", "Breast Cancer", "Stage II Breast Cancer", "Stage III Breast Cancer" ], "interventions": [ { "name": "T-DM1", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Excision of tumor/mastectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2015-01", "completion_date": "2028-01", "has_results": true, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-15T17:34:15.480Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02326974" }, { "nct_id": "NCT04090567", "title": "Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Germline BRCA1 Gene Mutation", "Germline BRCA2 Gene Mutation", "HER2/Neu Negative", "Metastatic Breast Carcinoma", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2020-07-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-15T17:34:15.480Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04090567" }, { "nct_id": "NCT00759642", "title": "Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2009-03", "completion_date": "2018-08-20", "has_results": true, "last_update_posted_date": "2019-07-01", "last_synced_at": "2026-10-15T17:34:15.480Z", "location_count": 3, "location_summary": "Kansas City, Kansas • Topeka, Kansas • Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Topeka", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00759642" }, { "nct_id": "NCT05579366", "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Epithelial Ovarian Cancer", "High Grade Serous Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Endometrial Cancer", "Non-small Cell Lung Cancer", "Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)", "Mesothelioma", "Breast Adenocarcinoma", "Triple Negative Breast Cancer", "Hormone Receptor-positive/Her2 Negative Breast Cancer", "Platinum-resistant Ovarian Cancer (PROC)", "Platinum Sensitive Ovarian Cancer (PSOC)", "Primary Refractory Ovarian Cancer", "Uterine Cancer", "Cervical Cancer" ], "interventions": [ { "name": "Rina-S", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Erythromycin", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 952, "start_date": "2022-12-07", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-15T17:34:15.480Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05579366" }, { "nct_id": "NCT04893109", "title": "ATEMPT 2.0: Adjuvant T-DM1 vs TH", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2-positive Breast Cancer" ], "interventions": [ { "name": "trastuzumab-emtansine", "type": "DRUG" }, { "name": "Trastuzumab SC", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2021-06-16", "completion_date": "2029-05-01", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-15T17:34:15.480Z", "location_count": 53, "location_summary": "San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 44 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Derby", "state": "Connecticut" }, { "city": "Fairfield", "state": "Connecticut" }, { "city": "Glastonbury", "state": "Connecticut" }, { "city": "Greenwich", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04893109" }, { "nct_id": "NCT04872166", "title": "A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Breast Cancer" ], "interventions": [ { "name": "BTX-A51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Edgewood Oncology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2021-06-07", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-10-15T17:34:15.480Z", "location_count": 6, "location_summary": "Lake Mary, Florida • Sarasota, Florida • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Lake Mary", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04872166" } ] }